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ABSTRACT The gp41 subunit of the envelope protein
complex from human and simian immunodeficiency viruses
(HIV and SIV) mediates membrane fusion during viral entry.
The crystal structure of the HIV-1 gp41 ectodomain core in its
proposed fusion-active state is a six-helix bundle. Here we
have reconstituted the core of the SIV gp41 ectodomain with
two synthetic peptides called SIV N36 and SIV C34, which
form a highly helical trimer of heterodimers. The 2.2 Å
resolution crystal structure of this SIV N36yC34 complex is
very similar to the analogous structure in HIV-1 gp41. In both
structures, three N36 helices form a central trimeric coiled
coil. Three C34 helices pack in an antiparallel orientation into
highly conserved, hydrophobic grooves along the surface of
this coiled coil. The conserved nature of the N36-C34 interface
suggests that the HIV-1 and SIV peptides are functionally
interchangeable. Indeed, a heterotypic complex between
HIV-1 N36 and SIV C34 peptides is highly helical and stable.
Moreover, as with HIV-1 C34, the SIV C34 peptide is a potent
inhibitor of HIV-1 infection. These results identify conserved
packing interactions between the N and C helices of gp41 and
have implications for the development of C peptide analogs
with broad inhibitory activity.
Human and simian immunodeficiency viruses (HIV and SIV)
use envelope glycoproteins to enter cells. The envelope gly-
coprotein complex consists of the surface subunit gp120 and
the transmembrane subunit gp41, which are produced through
proteolytic cleavage of the precursor gp160. gp120 binds to
CD4 and one of several coreceptors that are members of the
chemokine receptor family. Subsequently, gp41 undergoes
conformational changes that facilitate fusion of viral and host
cell membranes (reviewed in ref. 1). Structural studies of these
envelope proteins will be essential in elucidating the mecha-
nism of membrane fusion in these viruses.
The gp41 ectodomain contains several notable features (Fig.
1). It has a fusion peptide at the amino terminus that is thought
to insert directly into the target membrane during the mem-
brane fusion process. Carboxyl-terminal to the fusion peptide
are two regions containing 4,3 hydrophobic (heptad) repeats,
sequence motifs suggestive of coiled-coil structures. We have
used protein-dissection methods to identify stable, protease-
resistant cores in the ectodomains of gp41 from HIV-1 (2, 3)
and SIV (4). In both cases, the core consists of two peptides,
termed N and C peptides, that correspond to the two regions
with hydrophobic heptad repeats. These biophysical studies
show that the N and C peptides form a stable, helical trimer
of heterodimers (2, 4).
Crystallographic analysis of the HIV-1 gp41 core confirmed
that the NyC complex is a 6-helix bundle in which three N
helices form an interior, trimeric coiled coil (5–7). Three C
helices pack in an antiparallel orientation into hydrophobic
grooves on the surface of the N peptide coiled coil. This
structure likely represents the fusion-active conformation of
HIV-1 gp41 and resembles the fusion-active conformation of
the transmembrane fusion proteins of influenza (8) and Molo-
ney murine leukemia virus (9). Interestingly, synthetic C
peptides are potent inhibitors of infection for both laboratory-
adapted strains and primary isolates of HIV-1 (10, 11). These
C peptides likely inhibit infection, in a dominant-negative
manner, by binding to a transiently exposed, coiled-coil trimer
formed by the N peptide region of intact gp41 (reviewed in ref.
1).
A high-resolution structure of the related SIV gp41 core
would contribute to our understanding of HIV-2, the second
subtype of HIV. The envelope proteins of HIV-2 are sero-
logically distinct from those of HIV-1, but are closely related
to those of SIV. Sequence analysis indicates that SIV and
HIV-2 are closely related viruses (12, 13). HIV-2 infection in
humans can lead to the development of AIDS, although the
virus appears to be less pathogenic than HIV-1. A detailed
structure of the SIV gp41 core also would allow a direct
comparison of its helical interactions with those in HIV-1
gp41. Such a comparison could have implications for the design
and development of drugs based on C peptide analogs.
In our current study, we have reconstituted the core of the
SIV gp41 ectodomain by using two synthetic peptides called
SIV N36 and SIV C34. Each of these peptides in isolation is
poorly structured, but they form a highly helical complex when
mixed together. Crystallographic analysis of the SIV N36yC34
complex at 2.2 Å resolution reveals a trimeric structure that is
remarkably similar to the analogous complex from HIV-1
gp41. This high degree of structural conservation motivated us
to study the biophysical properties of a heterotypic complex
between HIV-1 N36 and SIV C34. We find that such a hybrid
is highly helical and stable. Moreover, the SIV C34 peptide is
a potent inhibitor of HIV-1 infection. These results demon-
strate that divergent immunodeficiency viruses contain enve-
lope proteins that are highly conserved structurally and func-
tionally, and they provide a structural explanation for the
broad inhibitory activity of the C peptides.
MATERIALS AND METHODS
Peptides and CD Spectroscopy. SIV N36 and SIV C34
peptides (sequences shown in Fig. 1) were synthesized by using
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f luorenylmethoxycarbonyl peptide chemistry. Both peptides
were acetylated at the amino termini and amidated at the
carboxyl termini. After cleavage from the resin, the peptides
were desalted on a Sephadex G-25 column (Pharmacia) and
lyophilized. The N36 peptide was then dissolved in water and
purified by reverse-phase HPLC (Waters) with a Vydac C18
preparative column (water-acetonitrile gradient in the pres-
ence of 0.1% trif luoroacetic acid). The C34 peptide, because
of its lower solubility at low pH, was purified by using a Jupiter
C18 preparative column at pH 6.8 (water-acetonitrile gradient
in the presence of 50 mM triethylamine-acetic acid buffer).
The peptide identities were checked by MALDI mass spec-
trometry (Voyager Elite, PerSeptive Biosystems). CD spec-
troscopy was performed in PBS (50 mM sodium phosphate, pH
7.0y150 mM NaCl) on an Aviv Model 62DS CD spectrometer
(Aviv Associates, Lakewood, NJ) as described previously (2).
Peptide concentration was determined by absorbance at 280
nm in 6 M guanidine hydrochloride (14).
Crystallization and Structure Determination. Stocks of
purified N36 and C34 peptide were dissolved in water and 10
mM sodium phosphate, pH 7.5, respectively. Equimolar
amounts of N36 and C34 were mixed, and the final protein
concentration was adjusted to 10 mgyml. Initial crystallization
conditions were found by using the vapor diffusion method
with sparse matrix crystallization kits (Crystal Screen I and II,
Hampton Research, Riverside, CA) and then optimized. Sev-
eral crystal forms were obtained, but the best diffracting
crystals were grown by equilibrating 4-ml drops (protein solu-
tion mixed 1:1 with reservoir solution) against a reservoir
solution containing 18–19% PEG8000y0.1 M sodium cacody-
late (adjusted to pH 6.5 with HCl)y0.2 M magnesium acetate.
Crystals belong to space group P212121 (a 5 55.74 Å, b 5 57.59
Å, and c 5 66.75 Å; a 5 b 5 g 5 90°). The appearance of one
trimer in the asymmetric unit results in a solvent content of
0.44 (15). The crystals demonstrate high mosaicity and diffract
anisotropically to a maximum resolution of 1.9 Å, but to only
2.2 Å in the orthogonal directions. Isomorphous crystals of
similar size also were grown by using 30% PEG4000y0.1 M
FIG. 2. CD spectra of SIV N36 and C34 peptides. CD spectra of
SIV N36 (), SIV C34 (), and the SIV N36 C34 complex (r) in PBS.
The predicted spectrum for noninteracting peptides (e) is shown for
comparison. Inset shows the thermal dependence of the CD signal at
222 nm for the SIV N36yC34 complex.
FIG. 3. Stereoviews of representative electron density maps. (A)
Initial 2Fo-Fc map after density modification and phase improvement
with DM (19) superimposed onto the initial molecular replacement
solution model. A shift of the N36 helix (left side of figure) and other
clear differences between the trial model and the observed density are
seen (white arrows). (B) Final 2Fo-Fc map superimposed onto the
refined model. Water molecules are indicated with small, red balls.
Both maps are contoured at 1.5 s. Figures were generated with O (20).
Table 1. Data collection and refinement statistics
Data collection
Highest resolution, Å 2.20
Observed reflections 52,353
Unique reflections 11,157
Completeness, % 96.9
Rmerge* 0.058
Refinement
Resolution, Å 20.0–2.20
Protein nonhydrogen atoms 1,809
Water molecules 184
Rcryst† 0.211
Rfree† 0.288
Average B-factor, Å2 36.2
rmsd from ideal geometry
Bond length, Å 0.009
Bond angles, ° 1.1
Torsion angles, ° 20.8
*Rmerge 5 SSjuIj(hkl) 2 ^I(hkl)& uySu ^I(hkl)&u, where Ij is the intensity
measurement for reflection j and ^I& is the mean intensity over j
reflections.
†Rcryst (Rfree) 5 SiFobs(hkl)u 2 uFcalc(hkl)iySuFobs(hkl)u, where Fobs
and Fcalc are observed and calculated structure factors, respectively.
Statistics are given for F . 2s. Ten percent of the reflections were
excluded from refinement and used to calculate Rfree.
FIG. 1. A schematic view of gp41, showing the locations of the N36
and C34 peptides from SIV and HIV-1. Identical residues between the
SIV and HIV-1 peptides are indicated with a bar, and similar residues
are indicated by dots. To facilitate comparisons between the HIV-1
and SIV structures, the peptide residues are numbered according to
their positions in HIV-1 gp160 (HXB2 strain; GenBank accession no.
K03455). For the SIV peptides (SIV Mac239 strain; GenBank acces-
sion no. M33262), N36 actually corresponds to positions 559–594, and
C34 corresponds to 637–670. The 4,3 hydrophobic repeats are indi-
cated with black shading. FP, fusion peptide; SOS, disulfide bond; TM,
transmembrane region; CYTO, cytoplasmic domain.
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TriszHCl, pH 8.5y0.2 M MgCl2, but their diffraction did not
exceed 2.3 Å.
For data collection, crystals were harvested and flash frozen
from a drop containing reservoir solution plus 10% 2-methyl-
2,4-pentanediol. Diffraction data were collected at 100 K by using
an X-stream cryosystem and an R-AXIS IV detector mounted on
a Rigaku RU300 rotating-anode x-ray generator (Molecular
Structure, The Woodlands, TX). Diffraction intensities were
integrated by using the DENZO and SCALEPACK software (16) and
reduced to structure factors by using the program TRUNCATE
from the CCP4 program suite (17). The structure of SIV N36y
C34 was solved by molecular replacement by using AMORE (18),
with an SIV N36yC34 model built from the x-ray structure of
HIV-1 N36yC34 (5). Solvent flattening, histogram matching, and
3-fold noncrystallographic averaging with the program DM (19)
were used to remove model bias. This produced an electron
density map of good quality, which clearly revealed differences
from the initial model (Fig. 3A). Noncrystallographic symmetry
restraints were not used in the refinement. Density interpretation
and model building were done with the program O (20). Bulk
solvent and anisotropic overall B-factor corrections, as imple-
mented in the programs X-PLOR (21) and REFMAC (17), were
crucial for crystallographic refinement of SIV N36yC34 (Table
1).
Viral Fusion Assay. The inhibitory activity of HIV-1 and
SIV C34 peptides was determined by using a recombinant
luciferase-encoding HIV-1 (22). This replication-incompetent
virus was produced by cotransfection of 293T cells with the
plasmid NL43LucR–E– (22) and the HXB2 gp160 expression
vector pCMVHXB2 gp160 (D.C.C. and P.S.K., unpublished
data). Viral supernatants were used to infect HOST4LES cells
(N. Landau, National Institutes of Health AIDS Reagent
Program) in the presence of varying concentrations of peptide
to obtain a dose-response curve. Each infection was done in
triplicate. Cell lysates were prepared 48 hr postinfection, and
luciferase activity was measured in a Wallac AutoLumat
LB953 luminometer (EG & G, Salem, MA).
RESULTS
Stability of the SIV N36yC34 Complex in Solution. CD
spectra for SIV N36 and SIV C34 show that neither peptide in
isolation has significant helical structure. However, when SIV
N36 and C34 are mixed together in equimolar amounts, there
is a large increase in helicity (Fig. 2). In this assay, the SIV
N36yC34 complex is estimated to be 70% helical. Upon
thermal denaturation, this complex unfolds cooperatively and
reversibly with a transition midpoint of 40°C (Fig. 2). The
corresponding HIV-1 N36yC34 complex has an apparent Tm
of 66°C (Fig. 6A) (3).
B C D
A
FIG. 4. Structure of SIV N36yC34 complex and comparison with that of HIV-1. (A) Stereoview from the side. The amino termini of N36 and
the carboxyl termini of C34 are at the top of the figure. Helices in the N36 coiled-coil trimer from SIV (blue) and HIV-1 (yellow) were used for
the superposition. The inner N36 coiled-coil trimers superimpose well; however, a pronounced shift in the central region of the outer C34 helices
is visible. (B) View from the top, along the noncrystallographic 3-fold axis. The same color coding is used. (C) A cross-section of the SIV ectodomain
composed almost exclusively of glutamine residues, six of which are conserved in the HIV ectodomain sequence and two that are conservatively
replaced by asparagines. Glutamine side chains are involved in a web of hydrogen bonds that also involve some carbonyl oxygens of the main chain.
(D) A cross-section of the SIV N36yC34 structure near the conserved, deep hydrophobic cavity involving three tryptophan residues. Figures were
generated with GRASP (28).
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Crystal Structure of the SIV gp41 Core. Crystals of the SIV
N36yC34 complex are obtained by using the hanging-drop
vapor-diffusion method. Crystal density calculations (15) in-
dicate that the SIV N36yC34 crystals contain one N36yC34
trimer in the asymmetric unit; each monomer is related by an
approximate noncrystallographic 3-fold axis. In contrast, the
crystal forms of the HIV-1 gp41 core contain trimers centered
on a crystallographic 3-fold axis (5–7). Using the molecular
replacement method, various trimeric SIV N36yC34 models
based on the HIV-1 ectodomain structure yielded the same
rotation–translation solution. This solution was consistent with
the orientation of the noncrystallographic 3-fold axis deduced
from a self-rotation function. Phase improvement with DM (19)
increased the quality of the initial electron density map and
served to reduce model bias, as indicated by the appearance of
clear 2Fo-Fc electron density not dictated by the trial model
(Fig. 3A). The final 2Fo-Fc electron density map is of good
quality (Fig. 3B) and reveals the positions of all the amino acid
residues except for a few disordered side chains at the helix
termini and on the surface.
The overall topology of the SIV gp41 core is the same as that
of the HIV gp41 core. Three SIV N36 helices form a central,
parallel coiled coil with a left-handed superhelical pitch,
whereas three C34 helices pack, in an antiparallel orientation,
into grooves along the surface of the N36 coiled coil (Fig. 4 A
and B). The interface between each C34 helix and the N36 core
is predominantly hydrophobic. The root mean square devia-
tion (rmsd) between all Ca atoms of the N36 coiled-coil core
in SIV and HIV is 0.54 Å. If Ca atoms of the entire structure
are used for superposition, the rmsd increases to 0.92 Å
because of the pronounced shift and bending of the C34 helix
in the SIV structure (Fig. 4A). The shift is most pronounced
near Gln-640, in the middle of the C34 helix, where the rmsd
is 2.0–2.5 Å.
Conserved Helical Interactions. Two notable features of the
N36-C34 interface are conserved between the SIV and HIV-1
gp41 structures. First, although most of the N36-C34 interface
involves hydrophobic interactions, one layer of interactions is
polar in nature and includes conserved clusters of glutamines
(Fig. 4C). The SIV N36 sequence contains five glutamines in
a row (Fig. 1); it remains to be determined whether there is any
relationship between the glutamine clusters seen here (Fig.
4C) and those found in polyglutamine repeats implicated in
neurological diseases (23). Second, each of the grooves on the
surface of the SIV N36 coiled coil contains a deep cavity lined
by hydrophobic side chains from two N36 helices. The side
chains of two tryptophans and a valine (isoleucine in the case
of HIV-1) from the C34 helices pack into this cavity (Figs. 4D
and 5B). A conserved salt bridge is formed on a side of the
cavity between Lys-574 from N36 and Glu-632 from C34 (Fig.
4D).
The analogous deep cavity in the N36 coiled coil of HIV
gp41 has been suggested to be a potential drug target (5).
Three reasons for this suggestion are: (i) earlier genetic studies
indicate that two of the N36 residues that form the cavity
(Leu-568 and Trp-571) are critical for membrane-fusion ac-
tivity (24), (ii) the N36 residues that form the cavity are highly
conserved in different HIV-1 isolates, and even between
HIV-1 and SIV, so that drug-escape mutants are expected to
be less frequent, and (iii) the combined molecular mass of the
C34 residues that insert into the N36 cavity is '600 Da, which
is within the size range for the development of orally bioavail-
able, small-molecule drugs.
For effective drug design, it is crucial to obtain an accurate,
high-resolution view of this cavity and the residues that project
into it. However, the three existing HIV-1 gp41 crystal struc-
tures (5–7) show different rotamers for two key residues that
are involved in forming the cavity: Trp-571 of N36 and Trp-628
of C34 (Fig. 5A). Our previous crystallographic analysis of
HIV-1 gp41 showed unambiguous experimental electron den-
sity in this region (see figure 2 in ref. 5). These side chain
discrepancies may be secondary to differences in crystal
packing contacts, the use of different crystal forms, chain
termini effects, or an inherent flexibility in these side chains.
FIG. 5. The conserved hydrophobic cavity on the surface of the N36 coiled coil. (A) Structural overlay of the published HIV-1 gp41 ectodomain
structures. The three structures [Chan et al. (5), yellow; Weissenhorn et al. (6), red; and Tan et al. (7), green] deviate substantially in this region.
(B) Interactions in the N36 hydrophobic cavity of SIV (blue) are most similar to the Chan et al. (5) HIV-1 structure (yellow). The same superposition
as in Fig. 4 A and B was used. The SIV N36 coiled coil is represented as a molecular surface, and the C34 helices are shown as ribbons with selected
side chains. The molecular surface is colored white for residues that are identical in SIV and HIV, and green for residues that are not identical.
Figures were generated with GRASP (28).
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It is also possible that in one study (7) Trp-628 may be distorted
because of an artificial linker that immediately precedes it,
whereas in a second study (6) Trp-628 may be poorly ordered,
as suggested by very high individual atomic B factors.
The SIV structure described here is highly consistent (Fig.
5B) with the HIV-1 gp41 structure that we described previ-
ously (5). Because this HIV-1 structure was used to solve the
SIV gp41 structure by molecular replacement, we were con-
cerned that these similarities might arise from model bias.
However, electron density for key residues that form the cavity
(e.g., Leu-568, Val-570, Trp-571, Gly-572, Thr-573, Asn-575,
Leu-576, and Gln-577 of N36 and Trp-628, Trp-631, and
Val-635 of C34) was unambiguous after density modification
(19) (Fig. 3A). Moreover, each of these residues was confirmed
with simulated annealing omit maps calculated with X-PLOR
(21). Chain termini effects are unlikely to explain the similar
side chain conformations observed with Trp-628, because
preliminary analysis of a larger SIV gp41 construct (V.N.M.
and P.S.K., unpublished observations) in a distinct crystal form
indicates the same side chain conformations.
Heterotypic Complexes of the gp41 Core. The remarkable
conservation of the N–C interface suggests that the N and C
peptides of SIV and HIV-1 might be functionally interchange-
able, at least in the formation of this six-helix structure. Simple
modeling indicates that the SIV C34 helix can fit easily into the
hydrophobic groove on the surface of the HIV-1 N36 core.
Indeed, CD measurements show that a heterotypic complex
consisting of HIV-1 N36 and SIV C34 is highly helical (Fig. 6A
Inset). Remarkably, the apparent Tm of this heterotypic com-
plex is 62°C, close to that of the HIV-1 gp41 core (Tm 5 66°C;
Fig. 6A), and significantly greater than that of the SIV gp41
core (Tm 5 40°C; Fig. 2).
The high stability of this heterotypic complex suggests that
SIV C34, like HIV-1 C34, might inhibit HIV-1 infection.
Indeed, SIV C34 potently inhibited infection by HIV-1 (HXB2
strain) with an IC50 of 2.2 6 0.2 nM (mean 6 SE), compared
with an IC50 of 1.3 6 0.07 nM for HIV-1 C34 (Fig. 6B).
DISCUSSION
Although the similarity of the HIV-1 and SIV gp41 core
structures was anticipated (4), several features of SIV and
HIV-1 envelope proteins are different. First, the SIV envelope
proteins are serologically related to those of HIV-2 but are
distinct from those of HIV-1 (12). These serological relations
are well supported by phylogenetic sequence analysis of these
lentiviruses. Second, the gp120ygp41 complex of SIV appears
to be more tightly associated than that of HIV-1, at least when
compared with some laboratory-adapted strains of HIV-1,
including the HXB2 strain (25, 26). Finally, the gp120 subunit
of SIV has been reported to bind CD4 with lower affinity than
HIV-1 gp120 (26).
A comparison of the HIV-1 and SIV gp41 cores reveals a
high degree of structural similarity. The overall structure of
both complexes consists of a six-helix bundle, in which three N
helices form an interior, parallel coiled coil. Three C34 helices
wrap around the outside of this coiled coil to form a highly
conserved interface. These structural similarities indicate that
the fusion mechanisms of HIV-1 and SIV are closely related.
The high degree of similarity at the interfaces between the
N and C peptide helices in the HIV-1 and SIV gp41 cores
provides a structural explanation for the broad inhibitory
activity of the C peptides. C peptides (derived from the
laboratory-adapted strain HXB2) potently inhibit a wide range
of HIV-1 isolates, including primary isolates that are typically
resistant to neutralization by soluble CD4 and neutralizing
antibodies (10, 11). At higher concentrations, the C peptide
DP178 also is capable of inhibiting HIV-2 strains (11, 27). We
show that SIV C34 is a potent inhibitor of HIV-1 infection.
Our results reinforce the notion that future development of C
peptide analogs should target conserved structural features of
the N36 coiled coil.
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